Set against a backdrop of rising concern about the cost of insulin, the FDA held a hearing about biosimilar insulins Monday, 10 months before the products transition in March 2020 from the Food Drug and Cosmetic Act to biologics under the Public Health Service Act.
Set against a backdrop of rising concern about the cost of insulin, the FDA held a hearing about biosimilar insulins Monday, 10 months before the products transition in March 2020 from the Food Drug and Cosmetic (FD&C) Act to biologics under the Public Health Service (PHS) Act.
The meeting also came a few days after the FDA released interchangeability guidance for biosimilars. According to remarks made by FDA Acting Commissioner Ned Sharpless, MD, the guidance will help keep prices low, while the transition to a new approval process will speed insulin competition.
The FDA workshop heard from a variety of stakeholders, including Vizient, Inc; Eli Lilly, maker of insulin lispro; Mylan; the JDRF; the American Diabetes Association; and Christine Simmon, of the Association for Accessible Medicines, to name a few.
“We encourage the FDA to build on its significant experience with insulin and foster efficient development of biosimilar insulins to lower costs and increase access for America’s diabetes patients,” said Simmon. “We urge the agency to continue educating providers and patients that transition from a reference product to a non-interchangeable biosimilar will not result in changes to safety or effectiveness.”
Those testifying gave different perspectives depending on their relationship to insulin, as noted in one report.
Mylan, which has so far tried and failed to get FDA approval for a follow-on insulin glargine referencing Lantus, said that the FDA should allow regulators to use previous trial findings or published literature in order to approve a follow-on product.
Meanwhile, Eli Lilly, which makes an insulin lispro injection (Humalog) and recently announced an authorized generic, called for switching studies and said that it gives more backing to the idea that the follow-ons will not generate immunogenicity.
Others testifying at the meeting explained how patients switch between insulins currently, which prompted the issue as to why interchangeable insulins and follow-on, or insulin biosimilars, need to reside in 2 separate categories.
Mariana P. Socal, MD, an assistant scientist at the Johns Hopkins Bloomberg School of Public Health, said there might be unintended consequences with the 2 separate designations, which patients might find confusing, according to S&P Global Market Intelligence.
For her part, Simmon, of AAM, drew similarities between insulin issues and the biosimilar market overall. “The insulin market in the US is a direct reflection of issues facing biosimilar broadly. The current insulin market lacks significant competition to the detriment of patient access and health and has been characterized as a public health crisis,” she said in her remarks.
“The combination of regulatory challenges, over-patenting to stave off competition, and anti-competitive rebating and contracting tactics by brand firms has been the cause of the lack of competition,” she said. Increases in list price impact insulin affordability, Simmon noted, affecting patient adherence.
Six of the most highly-used brand name insulins increased in list price by more than 500% from 2006 to 2015, she said.
The nation’s largest group purchasing organization, Vizient, said it fully endorses the scientific principles of biosimilarity, and “we believe that molecules necessary to create insulin are well suited for the creation of a biosimilar option for providers and patients,” according to a statement from Steven Lucio, PharmD, BCPS, vice president, pharmacy solutions.
“Insulin biosimilars, once approved, will bring much needed, new competition to the market and will offer more affordable treatment options to patients with diabetes.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.